Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Neurology

Managing Life with FENIB: Treatment and Support

At a Glance

FENIB has no cure that stops abnormal neuroserpin protein clumping, so care focuses on seizures and muscle jerks, safe swallowing, mobility, coordinated specialists, and family quality of life. Gene editing and other new treatments remain laboratory research, not established human care.

Managing Familial Encephalopathy with Neuroserpin Inclusion Bodies (FENIB) is a long-term commitment that requires a dedicated team. Because there is currently no cure or treatment that can stop the underlying clumping of the neuroserpin protein, the goal of medical care involves supportive (palliative) care—focusing on maximizing comfort, managing symptoms, and supporting your family’s quality of life alongside active neurological treatments [1].

The Challenge of Seizure Management

The most difficult symptom to treat in FENIB is often the combination of seizures and myoclonus (muscle jerks). In a small review of 12 documented cases, 9 patients did not respond to standard antiseizure medications (ASMs) [2].

Because these symptoms are often “refractory” (resistant to treatment), your neurologist may need to try several different drug combinations. It is important to work with an epileptologist—a neurologist who specializes specifically in epilepsy—to find a balance between controlling the jerks and avoiding side effects like extreme drowsiness or confusion [2][3]. Never start, stop, or change doses of antiseizure medications without direct instructions from your treating team.

Assembling Your Care Team

Since FENIB affects so many parts of the body and mind, you will likely need a “roster” of specialists to help navigate the different stages of the disease:

  • Neurologist/Epileptologist: To manage seizures and monitor brain health.
  • Geneticist & Genetic Counselor: To help interpret the specific SERPINI1 mutation and discuss what it means for other family members [4].
  • Physical Therapist (PT): To assist with mobility, balance, and preventing falls [5].
  • Occupational Therapist (OT): To help adapt your home and find tools for daily tasks like dressing or bathing [6].
  • Speech-Language Pathologist (SLP): To monitor for swallowing difficulties (dysphagia) and help with communication as the disease progresses [7].

Proactive Daily Management

Wait-and-see is rarely the best approach. Being proactive can prevent complications like pneumonia or injury from falls. (Note that this evidence is extrapolated from related disorders and individual assessment is required.)

  • Swallowing and Nutrition: In related disorders, patients often struggle with moving food to the back of the throat or may experience “silent aspiration” (food or liquid entering the lungs without causing a cough) [8]. Evaluations by a speech specialist based on symptoms like weight loss or coughing can help you adjust food textures and learn safe feeding techniques [7][5].
  • Mobility Support: Frequent falls are common as coordination and muscle control decline [9]. A physical therapist can recommend assistive devices—like specialized walkers or wheelchairs—before an injury occurs [6].
  • Trigger Management: Some patients find that fatigue, stress, or sudden bright lights can trigger an increase in muscle jerks. While environmental changes do not reliably prevent seizures, maintaining a calm, predictable environment and ensuring adequate rest may help [10].

The Horizon: Experimental Research

You may read about “small molecules” or “gene editing” in the news. It is important to know that while this research is exciting, it is currently preclinical. This means it is being tested in labs, cells, or animal models, but is not yet available for human use [2][4].

Current areas of study include:

  • Small Molecules: Researchers are looking at compounds like embelin and EGCG (a component of green tea) to see if they can stop the neuroserpin protein from clumping [11][12].
  • Base Editing: A very early form of gene therapy is being tested in lab cells to see if the “broken” part of the SERPINI1 gene can be corrected [13].

Warning: These approaches have no established clinical benefit and should not be self-administered or substituted for prescribed care. Concentrated supplements can have dangerous interactions with antiseizure medications. They should only be considered in an appropriately regulated study. While these therapies offer hope for the future, the most important work right now is the day-to-day care that keeps your loved one safe, comfortable, and connected.

Common questions in this guide

What treatment is available for FENIB today?
There is currently no cure or treatment known to stop the abnormal clumping of neuroserpin protein in FENIB. Care focuses on controlling symptoms, preventing complications, maximizing comfort, and supporting quality of life with neurological and palliative care.
How are FENIB seizures and muscle jerks managed?
Seizures and myoclonus, or involuntary muscle jerks, can be resistant to standard antiseizure medicines. A neurologist who specializes in epilepsy may try different medicine combinations while balancing seizure control with side effects such as severe drowsiness or confusion. Do not start, stop, or change a medicine dose without the treating team’s instructions.
Which specialists should coordinate care for someone with FENIB?
Care may involve a neurologist or epileptologist, geneticist and genetic counselor, physical and occupational therapists, a speech-language pathologist, and a palliative care team. These specialists can address seizures, family genetic questions, mobility, daily activities, swallowing, communication, comfort, and caregiver needs. Ask the team to identify a clinician who will coordinate the overall plan.
What signs mean a person with FENIB needs a swallowing assessment?
Coughing during meals, taking much longer to eat, weight loss, or concerns that food or liquid is entering the lungs can signal a swallowing problem. A speech-language pathologist can evaluate swallowing and recommend safer food textures, feeding techniques, or other support. Some aspiration can occur without coughing, so discuss new eating or breathing concerns with the care team.
Can therapy help with falls and daily activities in FENIB?
Physical therapy can work on mobility and balance and recommend a walker or wheelchair before a fall causes injury. Occupational therapy can adapt the home and suggest tools for dressing, bathing, and other daily tasks. Early assessment may help preserve safety and independence as coordination and muscle control change.
Are gene editing, embelin, or EGCG treatments available for FENIB?
No. Base editing and compounds such as embelin and EGCG are still being studied in cells, laboratories, or animal models, and they have no established benefit for people with FENIB. Do not self-treat with concentrated supplements or replace prescribed care; these products may interact with antiseizure medicines and should only be considered in an appropriately regulated study.

Get notified when new evidence is published on Familial encephalopathy with neuroserpin inclusion bodies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    An Inducible Neural Stem Progenitor Cell Model for Testing Therapeutic Interventions Against Neurodegeneration FENIB.

    Giustini A, Maiocchi A, Serangeli I, et al.

    Drug development research 2025; (86(1)):e70041 doi:10.1002/ddr.70041.

    PMID: 39749681
  2. 2

    Role of SERPINI1 pathogenic variants in familial encephalopathy with neuroserpin inclusion bodies: A case report and literature review.

    Yang X, Fang Z, Yan L, et al.

    Seizure 2022; (103()):137-147 doi:10.1016/j.seizure.2022.11.008.

    PMID: 36417830
  3. 3

    Clinical features of neuronal intranuclear inclusion disease with seizures: a systematic literature review.

    Zhang J, Ling L, Xiang L, et al.

    Frontiers in neurology 2024; (15()):1387399 doi:10.3389/fneur.2024.1387399.

    PMID: 38707999
  4. 4

    Modeling and Correction of Protein Conformational Disease in iPSC-derived Neurons through Personalized Base Editing.

    Konishi CT, Mulaiese N, Butola T, et al.

    bioRxiv : the preprint server for biology 2024; doi:10.1101/2024.01.17.576134.

    PMID: 38293034
  5. 5

    Shifting Tides Toward a Proactive Patient-Centered Approach in Dysphagia Management of Neurodegenerative Disease.

    Rogus-Pulia NM, Plowman EK

    American journal of speech-language pathology 2020; (29(2S)):1094-1109 doi:10.1044/2020_AJSLP-19-00136.

    PMID: 32650651
  6. 6

    Palliative care principles in ALS.

    Shoesmith C

    Handbook of clinical neurology 2023; (191()):139-155 doi:10.1016/B978-0-12-824535-4.00007-0.

    PMID: 36599506
  7. 7

    Palliative Care in Amyotrophic Lateral Sclerosis.

    Mercadante S, Al-Husinat L

    Journal of pain and symptom management 2023; (66(4)):e485-e499 doi:10.1016/j.jpainsymman.2023.06.029.

    PMID: 37380145
  8. 8

    Neuronal intranuclear inclusion disease presenting with dysphagia: a report of three cases.

    Aoyagi Y, Taya M, Ohashi M, Saitoh E

    Neurocase 2020; (26(4)):252-257 doi:10.1080/13554794.2020.1788607.

    PMID: 32619141
  9. 9

    [A case of neuronal intranuclear inclusion disease with coexisting Alzheimer's disease biomarker signature in cerebrospinal fluid].

    Ono N, Maruyama G, Akaiwa Y, et al.

    Rinsho shinkeigaku = Clinical neurology 2025; (65(12)):912-915 doi:10.5692/clinicalneurol.cn-002153.

    PMID: 41285472
  10. 10

    Familial adult-onset neuronal intranuclear inclusion disease: A case report and literature review.

    Wei L, Wang J, Xu C, et al.

    Medicine 2024; (103(44)):e40279 doi:10.1097/MD.0000000000040279.

    PMID: 39496005
  11. 11

    Embelin binds to human neuroserpin and impairs its polymerisation.

    Saga G, Sessa F, Barbiroli A, et al.

    Scientific reports 2016; (6()):18769 doi:10.1038/srep18769.

    PMID: 26732982
  12. 12

    Structural targeting of a familial variant of neuroserpin (Ser52Arg) by epigallocatechin gallate binding that reduces polymerization and enhances the tissue plasminogen activator inhibition.

    Ahmad T, Zaidi FK, Siddiqui U, et al.

    Biochimica et biophysica acta. Proteins and proteomics 2026; (1874(4)):141140 doi:10.1016/j.bbapap.2026.141140.

    PMID: 41866009
  13. 13

    Modeling and correction of protein conformational disease in iPSC-derived neurons through personalized base editing.

    Konishi CT, Mulaiese N, Butola T, et al.

    Molecular therapy. Nucleic acids 2025; (36(1)):102441 doi:10.1016/j.omtn.2024.102441.

    PMID: 39877004

This page explains FENIB treatment and day-to-day support for informational purposes only and does not constitute medical advice. Your neurology team should guide medication changes, swallowing safety, supplements, and decisions about clinical research.